Loading...
Loading...
Jefferies reiterates its Buy rating and $31 price target on Body Central
BODY on positive pre-announcement for the fourth quarter.
Jefferies says, "BODY pre-announced 4Q sales numbers ahead of its presentation at the ICR conference later this week. Topline was better than expected and the company raised its EPS outlook to the high end of the prior range. We view this news very positively and remain buyers of this stock, especially given the current cheap valuation for a high growth name."
BODY closed at $23.15 per share on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in